Alcohol increases the incidence of oral and esophageal cancers, and smoking multiplies that risk
Reducing or stopping alcohol consumption decreases the risk of oral and esophageal cancers. Alcohol undeniably increases the risk of these cancers, and smoking multiplies that risk.

The International Agency for Research on Cancer (IARC) assessed the impact of alcohol consumption on the risk of seven different cancers. Its report was published in the prestigious New England Journal of Medicine.
According to the report, there is strong scientific evidence that reducing or stopping regular alcohol consumption reduces the risk of oral and esophageal cancers.
“A dry January is not enough, but reducing alcohol consumption permanently can significantly reduce the risk of all alcohol-related cancers, and at the same time also alcohol-related problems and other alcohol-related diseases,” says Professor Emeritus Mikko Salaspuro.
Mikko Salaspuro contributed to compiling the report. He has been studying the mechanisms of alcohol-related cancers for more than 30 years at the University of Helsinki and at HUS. Under Salaspuro's guidance, 11 doctoral theses and 62 scientific publications have been completed on the subject. These studies played a key role in the preparation of the report.
Alcohol is converted into a carcinogen in the body
Alcohol increases the risk of cancer when bacteria and yeasts in the body convert alcohol in the digestive tract into the cancer-causing acetaldehyde. Acetaldehyde is a DNA-binding compound that can cause carcinogenic mutations and inhibit the repair of chromosomal damage. Alcohol in itself is not carcinogenic.
Mikko Salaspuro's research team used genetic studies to establish a causal link between acetaldehyde and upper gastrointestinal cancers, and to investigate the factors that regulate acetaldehyde levels in saliva and colon contents during alcohol consumption.
Alcohol enters the intestines through the bloodstream. However, the effects of alcohol on the intestines are individual, and the report concludes that evidence for the cancer risk-reducing effect of stopping alcohol consumption is weak. According to the report, there is no evidence of the role of acetaldehyde in the mechanisms of liver and breast cancer development, but these are affected by alcohol in a roundabout way.
Smoking multiplies the risk of alcohol-induced cancer
The report also took into account Finnish studies on the interaction between regular smoking and alcohol: oral microbes produce twice as much acetaldehyde from ethanol in smokers as they do in non-smokers.
Tobacco smoke contains acetaldehyde, and Mikko Salaspuro's research team has shown that the acetaldehyde in tobacco smoke is partially soluble in saliva. Oral acetaldehyde exposure is seven times higher in alcohol drinkers and smokers than in alcohol drinkers who do not smoke.
The report states that alcohol and tobacco also cause a similar process of acetaldehyde formation in the pharynx and larynx. People who quit drinking alcohol have a 31% lower relative risk of developing laryngeal cancer compared to regular drinkers.
The authors of the report were invited by the International Agency for Research on Cancer (IARC) to review the scientific evidence on the risk and prevention of alcohol-related cancers. A book on the subject is also being published. The IARC is an international research institute under the World Health Organization (WHO) that brings together cancer researchers to study the incidence of cancer and find ways to prevent it.
In 2020, an estimated 741,300 people were diagnosed with alcohol-related cancer.
Link to the research article:
The IARC Perspective on Alcohol Reduction or Cessation and Cancer Risk
Contacts
Mikko SalaspuroProfessor EmeritusUniversity of Helsinki
Tel:+358 50 051 1689mikko.salaspuro@helsinki.fiVeronique Terrasse
Interview requests from international researchers
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our nearly 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
HUS-sammanslutningens styrelse sammanträder den 3 november30.10.2025 15:26:19 EET | Pressmeddelande
Sammanslutningens styrelse sammanträder måndagen den 3 november för att för första gången behandla HUS-sammanslutningens förslag till budget för 2026 samt verksamheten och ekonomin för januari–september 2025. Föredragningslistan för mötet finns här. Sammanslutningens styrelse leder HUS verksamhet, förvaltning och ekonomi. Sammanslutningens styrelse har 17 ledamöter och av dem är två företrädare för Helsingfors universitet. Sammanslutningens styrelse sammanträder cirka en gång per månad. HUS medietjänst betjänar medier måndag–torsdag kl. 10–16, fredag kl. 10–15 på numret 050 427 2875 eller per e-post på viestinta@hus.fi. Se avvikande öppettider.
HUSin yhtymähallitus kokoontuu 3.11.30.10.2025 15:26:19 EET | Tiedote
Yhtymähallitus kokoontuu maanantaina 3.11. käsittelemään ensimmäistä kertaa HUS-yhtymän vuoden 2026 talousarvioesitystä sekä tammi-syyskuun 2025 toimintaa ja taloutta. Kokouksen esityslistan voi lukea täältä. Yhtymähallitus johtaa HUSin toimintaa, hallintoa ja taloutta. Yhtymähallituksessa on 17 jäsentä, joista kaksi on Helsingin yliopiston edustajia. Yhtymähallitus kokoontuu noin kerran kuukaudessa. HUSin mediapalvelu palvelee mediaa ma–to klo 10–16, pe klo 10–15 numerossa 050 427 2875 tai sähköpostitse viestinta@hus.fi. Katso poikkeusaukioloajat
Alla patienter som ska genomgå stötvågsbehandling av urinstenar behöver inte få antibiotika före behandlingen21.10.2025 07:47:57 EEST | Pressmeddelande
I en internationell prövning ledd av HUS undersöktes fördelarna, nackdelarna och behovet av antibiotika före stötvågsbehandling av urinstenar för att förebygga infektioner.
Kaikki potilaat eivät tarvitse antibioottia ennen virtsatiekivien murskaustoimenpidettä21.10.2025 07:47:57 EEST | Tiedote
HUSista johdetussa kansainvälisessä tutkimuksessa tarkasteltiin antibiootin hyötyjä, haittoja ja tarpeellisuutta ennen virtsakivien murskausta infektioiden ehkäisemiseksi.
Not all patients need antibiotics before shockwave lithotripsy for urolithiasis21.10.2025 07:47:57 EEST | Press release
An international study led by a HUS investigator examined the benefits, adverse effects, and necessity of antibiotics before shockwave lithotripsy in the prevention of infections.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom